Pacific Biosciences of California Inc 2025年季度报告

Form10-Q_____________________________________________________________________________________________ (Mark One)xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedJune 30, 2025 Or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number001-34899 Pacific Biosciences of California, Inc.(Exact name of registrant as specified in its charter)_____________________________________________________________________________________________ (650)521-8000(Registrant’s telephone number, including area code)_____________________________________________________________________________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.YesxNoo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of theExchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesoNox Number of shares outstanding of the issuer’s common stock as of July31, 2025:300,370,611. TABLE OF CONTENTS Item 1. Financial Statements (unaudited):Condensed Consolidated Balance Sheets as ofJune 30, 2025 and December 31, 20243Condensed Consolidated Statements of Operations and Comprehensive Loss for the Threeand SixMonths EndedJune 30, 2025 and 20244Condensed Consolidated Statements of Stockholders’ Equity for the Threeand SixMonths EndedJune 30, 2025 and 20245Condensed Consolidated Statements of Cash Flows for theSixMonths EndedJune 30, 2025 and20246Notes to Condensed Consolidated Financial Statements7Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations27Item 3. Quantitative and Qualitative Disclosures About Market Risk40Item 4. Controls and Procedures40PART II. OTHER INFORMATIONItem 1. Legal Proceedings41Item 1A. Risk Factors43Item 2. Unregistered Sales of Equity Securities and Use of Proceeds84Item 3. Defaults Upon Senior Securities84Item 4. Mine Safety Disclosures84Item 5. Other Information85Item 6. Exhibits86Signatures87 PART I. FINANCIAL INFORMATION See accompanyingnotesto the condensed consolidated financial statements. Balance at March 31, 2025Net lossOther comprehensive lossIssuance of common stock inconjunction with equity plansShare-based compensation expenseBalance at June 30, 2025 Balance at December 31, 2024Net lossOther comprehensive lossIssuance of common stock inconjunction with equity plansShare-based compensation expenseBalance at June 30, 2025 (In thousands)Balance at March 31, 2024Net lossOther comprehensive lossIssuance of common stock inconjunction with equity plansShare-based compensation expenseBalance at June 30, 2024 (In thousands)Balance at December 31, 2023Net lossOther comprehensive lossIssuance of common stock inconjunction with equity plansShare-based compensation expenseBalance at June 30, 2024 See accompanyingnotesto the condensed consolidated financial statements. Table of Contents PACIFIC BIOSCIENCES OF CALIFORNIA, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Business Overview We are a life science technology company that designs, develops, and manufactures advanced sequencing solutionsthat enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolvegenetically complex problems. Our products and technology, which include our HiFi long-read sequencing technology, address solutions across abroad set of applications including human germline sequencing, plant and animal sciences, infectious disease andmicrobiology, oncology, and other emerging applications. Our focus is on creating some of the world's most advanced sequencing